| Secondary |
| Product Used For Unknown Indication |
27.3% |
| Drug Use For Unknown Indication |
22.7% |
| Sepsis |
9.0% |
| Staphylococcal Infection |
7.7% |
| Device Related Infection |
3.3% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Staphylococcal Bacteraemia |
2.7% |
| Stent Placement |
2.7% |
| Arthritis |
2.3% |
| Arthritis Bacterial |
2.0% |
| Erysipelas |
2.0% |
| Hypertension |
2.0% |
| Osteoporosis |
2.0% |
| Septic Shock |
2.0% |
| Staphylococcal Sepsis |
2.0% |
| Abscess Limb |
1.7% |
| Hypotension |
1.7% |
| Pain |
1.7% |
| Ankylosing Spondylitis |
1.3% |
| Arthralgia |
1.3% |
|
| Thrombocytopenia |
17.5% |
| Toxic Skin Eruption |
11.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
9.5% |
| Rash Maculo-papular |
7.9% |
| Renal Failure Acute |
7.9% |
| Cytolytic Hepatitis |
6.3% |
| Myositis |
6.3% |
| Pancytopenia |
4.8% |
| Bicytopenia |
3.2% |
| Catheter Site Phlebitis |
3.2% |
| Hyperbilirubinaemia |
3.2% |
| Sepsis |
3.2% |
| Thrombophlebitis Superficial |
3.2% |
| Vitamin K Deficiency |
3.2% |
| Agranulocytosis |
1.6% |
| Anaemia |
1.6% |
| Anaemia Haemolytic Autoimmune |
1.6% |
| Aplastic Anaemia |
1.6% |
| Breast Abscess |
1.6% |
| Dermatitis Bullous |
1.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
23.4% |
| Product Used For Unknown Indication |
17.6% |
| Unevaluable Event |
7.7% |
| Pneumonia |
5.0% |
| Staphylococcal Infection |
4.5% |
| Arthritis Bacterial |
3.6% |
| Epilepsy |
3.6% |
| Sedation |
3.6% |
| Erysipelas |
3.2% |
| Lung Disorder |
3.2% |
| Agitation |
2.7% |
| Endocarditis Staphylococcal |
2.7% |
| Osteomyelitis |
2.7% |
| Sepsis |
2.7% |
| Status Epilepticus |
2.7% |
| Grand Mal Convulsion |
2.3% |
| Infection Prophylaxis |
2.3% |
| Myocardial Ischaemia |
2.3% |
| Parkinson's Disease |
2.3% |
| Staphylococcal Sepsis |
2.3% |
|
| Renal Failure |
10.9% |
| Eosinophilia |
6.5% |
| Hyponatraemia |
6.5% |
| Neutropenia |
6.5% |
| Rash Erythematous |
6.5% |
| Renal Failure Acute |
6.5% |
| Acute Generalised Exanthematous Pustulosis |
4.3% |
| Cholestasis |
4.3% |
| Haemolytic Anaemia |
4.3% |
| Hepatic Enzyme Increased |
4.3% |
| International Normalised Ratio Increased |
4.3% |
| Pulmonary Oedema |
4.3% |
| Rash Maculo-papular |
4.3% |
| Shock Haemorrhagic |
4.3% |
| Skin Lesion |
4.3% |
| Suicide Attempt |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Transaminases Increased |
4.3% |
| Agitation |
2.2% |
| Anaemia |
2.2% |
|
| Interacting |
| Product Used For Unknown Indication |
61.3% |
| Acute Promyelocytic Leukaemia |
22.6% |
| Drug Use For Unknown Indication |
6.5% |
| Infection |
3.2% |
| Insomnia |
3.2% |
| Phlebitis |
3.2% |
|
| Drug Interaction |
57.1% |
| Myositis |
28.6% |
| Haemarthrosis |
14.3% |
|
